Trial Profile
Multicenter Clinical Study Evaluating the Safety and Efficacy of Dasatinib Treatment and its Discontinuation in Patients with Chronic Phase Chronic Myelogenous Leukemia who had Reached Complete Molecular Response during Imatinib Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2020
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 02 Dec 2020 Status changed from recruiting to completed.
- 04 Mar 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
- 08 Feb 2012 New trial record